Diagnostics

Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold

by
Tempus to acquire Personalis for $1.5B, buying the MRD test it already commercialised

Deal Oncology/ Diagnostics/ MRD Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold Athithi Verma· 21 July 2026· 1 min read· Synopulse Tempus AI will acquire Personalis at $16.25 per share, a $1.5B enterprise value net of the stake Tempus already held. All-stock, with a cash option capped at 50 percent. … Read more

Stratipath And Roche Collaborate To Expand Access To Ai-powered Breast Cancer Diagnostics

by

Stratipath, a leader in AI-based precision diagnostic solutions, has announced a collaboration with Roche, the world’s largest biotechnology company and a global leader in in-vitro diagnostics. Through this partnership, Roche gains distribution rights to Stratipath’s AI-driven diagnostic tool, Stratipath Breast. This solution integrates seamlessly with Roche’s navify® Digital Pathology enterprise software, allowing users to perform … Read more